Form 10-Q - Quarterly report [Sections 13 or 15(d)]

S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Article too big to display. Click here to view on the SEC website

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma (NASDAQ:STRO)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Sutro Biopharma Charts.

Sutro Biopharma Inc News

Form 8-K - Current report
Tuesday 10 December 2024 (2 weeks ago) • Edgar (US Regulatory)

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Tuesday 10 December 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 3 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Thursday 14 November 2024 (1 month ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Wednesday 13 November 2024 (1 month ago) • Edgar (US Regulatory)

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights
Wednesday 13 November 2024 (1 month ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Tuesday 12 November 2024 (1 month ago) • Edgar (US Regulatory)

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference
Monday 4 November 2024 (2 months ago) • GlobeNewswire Inc.

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Friday 1 November 2024 (2 months ago) • GlobeNewswire Inc.

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Thursday 10 October 2024 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 20 September 2024 (3 months ago) • Edgar (US Regulatory)

More Sutro Biopharma Inc News Articles

Asia Broadband (PK)

Anavex Life Sciences

Lightwave Logic

Digital Brand Media and ... (PK)

Good Vibrations Shoes (PK)

Elite Pharmaceuticals (QB)

Bioelectronics (PK)

Fannie Mae (QB)

Northwest Biotherapeutics (QB)

Code Green Apparel (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions